102 results on '"Ganster C"'
Search Results
2. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
3. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
4. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
5. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): INITIALLY AND NEWLY ACQUIRED TP53 MUTATIONS IN PATIENTS WITH MDS WITH DEL(5Q) WITH/WITHOUT LENALIDOMIDE
6. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
7. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
8. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
9. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
10. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
11. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
12. P090 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
13. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
14. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
15. P015 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): INITIALLY AND NEWLY ACQUIRED TP53 MUTATIONS IN PATIENTS WITH MDS WITH DEL(5Q) WITH/WITHOUT LENALIDOMIDE
16. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
17. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
18. P05 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MDS WITH ISOLATED TRISOMY 8 AND DEL(20Q) – REALLY NOT MDS DEFINING?
19. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
20. Topic: AS02-Epidemiology
21. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
22. Comprehensive genetic characterization of circulating CD34+ cells of MDS patients by FISH- and SNP array analysis: V711
23. Loss of the Y chromosome in MDS: clonal marker or agerelated phenomenon?: V65
24. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
25. Loss of the Y Chromosome in MDS: Clonal abnormality or age-related accident?: V749
26. Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
27. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
28. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
29. Isolated der (1;7) fits well in the intermediate risk group of the cytogenetic scoring system for myelodysplastic syndromes
30. TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (>= 3 anomalies) Aberrant Karyotypes
31. A new, simple prognostic system for complex aberrant myelodysplastic syndromes and secondary AML
32. PF553 CLONES WITH COMPLEX ABERRATIONS AND TP53 MUTATIONS RESPOND TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
33. Genetic instability and TP53 alterations in MDS and sAML with complex aberrant karyotype
34. TARGETED DEEP SEQUENCING OF PERIPHERAL CD34+CELLS CAN REPRODUCE BONE MARROWMOLECULAR PROFILE IN MDS PATIENTS
35. Analysis of MDS patients by Targeted Deep Sequencing revealed comparable results for circulating CD34(+) blood cells and bone marrow aspirate
36. Iron-overload links to genetic instability in myelodysplastic syndromes
37. Nachweis einer signifikanten Korrelation von Eisenüberladung mit erhöhter genetischer Instabilität mittels umfassender genetischer Analysen bei Patienten mit Myelodysplastischen Syndromen
38. Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes
39. Targeted Deep Sequencing of Peripheral CD34+ Cells can Reproduce Bone Marrow Molecular Profile in MDS Patients
40. Increased Serum Ferritin and Genetic Instability in Myelodysplastic Syndromes
41. 175 - Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes
42. 267 - Targeted Deep Sequencing of Peripheral CD34+ Cells can Reproduce Bone Marrow Molecular Profile in MDS Patients
43. 54 - Increased Serum Ferritin and Genetic Instability in Myelodysplastic Syndromes
44. P-070 Clonality of loss of the Y-chromosome in MDS and its role in MDS evolution
45. P-062 Applicability of comprehensive cytogenetic analysis of peripheral blood of MDS patients by combined FISH and SNP-array analysis
46. 118 Comprehensive genetic characterization of MDS patients by CD34+ bone marrow and peripheral blood combining FISH-, SNP- and chromosome banding analysis
47. COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
48. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
49. Molecular taxonomy of myelodysplastic syndromes and its clinical implications.
50. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.